Ialt 48 patienter med CML i lymfoid blastfase fik dasatinib 70 2 gange daglig (42 resistente og 6 intolerante over for imatinib).
A total of 48 patients with lymphoid blast CML received dasatinib 70 mg twice daily (42 resistant and 6 intolerant to imatinib).